BioSpace
Episodes
Gilead’s Ouro Buy, J&J/Protagonist’s Approval, Aurinia’s Revamp, ACIP Confusion, More
25 Mar 2026
Contributed by Lukas
Immunology & inflammation stole the show this week, as Gilead dropped up to $2.1 billion for Ouro Medicines and its T cell engager OM336—an inve...
Inside the Race to Build the Next Generation of AI Drug Discovery Platforms
19 Mar 2026
Contributed by Lukas
In this episode, you'll be listening to Akshay Rai, principal, Healthcare & Biotech Investments at Premji Invest and Viswa Colluru, CEO and foun...
Kennedy’s Vaccine Agenda Stalled, Structure’s ‘Competitive’ Obesity Pill, Novo’s Warning Letter
18 Mar 2026
Contributed by Lukas
Biopharma’s weight loss warriors have led the news this week, with Structure Therapeutics and Rhythm Pharmaceuticals announcing new data. Structure ...
From Two Trials to One, Sponsors Face a Higher Standard
12 Mar 2026
Contributed by Lukas
In this episode of Denatured, you'll listen to Oxana Iliach, senior director of regulatory strategy at Certara and Vera Pomerantseva, director of ...
Prasad Out at FDA, Lawmaker Takes Action on Rare Disease Rejections and a Spate of Obesity Data
11 Mar 2026
Contributed by Lukas
After Friday’s news that Center for Biologics Evaluation & Research Chief Vinay Prasad will leave the FDA—again—at the end of April, stocks ...
Rising Amid Flurry of CAR T Deals, Stylus Proves Cell Therapy Is Not Dead
10 Mar 2026
Contributed by Lukas
Stylus Medicine CEO Emile Nuwaysir and Chief Scientific Officer Jason Fontenot speak with BioSpace about the biotech's work on next-generation ...
From Grants to Family Offices: Building a Unified Financing Strategy in Biotech
05 Mar 2026
Contributed by Lukas
In this Denatured episode, Jennifer C. Smith-Parker speaks to Ram May-Ron, managing partner at FreeMind Group, and Ravi Kiron, managing director at Bi...
UniQure’s Delay, REGENXBIO’s Rejection Explained, Sarepta’s Ingram Steps Down, More
04 Mar 2026
Contributed by Lukas
The FDA is dominating the headlines once again thisweek. Days after FDA Commissioner Marty Makary appeared to question uniQure’s gene therapy cand...
ALS Advances Unite Patients and Pharma on Novel Targets, Biomarker Breakthroughs
26 Feb 2026
Contributed by Lukas
In this episode, you'll be listening to Indu Navar, CEO and founder of EverythingALS and Dr. Olga Uspenskaya, chief medical officer at VectorY The...
Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval
25 Feb 2026
Contributed by Lukas
Eli Lilly notches another win over Novo Nordisk, as Zepbound bests CagriSema in a head-to-head trial sponsored by Novo; The FDA kicked off Rare Di...
Corsera Eyes Two-Pronged Approach To Tackle Leading Cardiovascular Killer
24 Feb 2026
Contributed by Lukas
Corsera Health’s Chief Operating Officer Rena Denoncourt and CFO Meredith Kaya speak with BioSpace about the biotech’s mission and vision fo...
Redefining Obesity Treatment Beyond GLP-1 Limits
19 Feb 2026
Contributed by Lukas
In this episode, you'll be listening to Jane Hughes, President of R&D and Co Founder of Verdiva Bio, and Jon Rees, CEO and cofounder of MitoRx...
Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders
18 Feb 2026
Contributed by Lukas
Last week, the FDA declined to review Moderna’s mRNA-based flu vaccine, with Center for Biologics Evaluation and Research Director Vinay Prasad hims...
As FDA Moves Away From Animal Testing, AI and Organoids Can Shine
17 Feb 2026
Contributed by Lukas
Last year, the FDA announced it would be phasingout animal testing requirements for some therapies. The NIHfollowed suit. According to Thomas Hartung,...
Digital Pathology, AI and the Future of ADCs and HER2 Cancer Treatment
12 Feb 2026
Contributed by Lukas
In this episode of Denatured, Jennifer C. Smith-Parker speaks with Dr. Rob Monroe, Vice President and Chief Scientific Officer of Oncology at Danaher ...
Weight Loss Drama Compounds on Heels of Novo, Lilly Earnings, Plus Gene Therapy News
11 Feb 2026
Contributed by Lukas
Last Thursday, Hims & Hers launched a compounded versionof Novo’s oral Wegovy, approved just before Christmas and launched in early January. Nov...
Programmable RNA 2.0: Beyond the First mRNA Revolution
05 Feb 2026
Contributed by Lukas
In this episode of Denatured, Jennifer C. Smith-Parker speaks to Erik Digman Wiklud, CEO of Circio and Jacob Becraft, CO-founder and CEO of Strand The...
Pfizer’s Metsera Data, 2025 Earnings, the FDA and REGENXBIO, Psychedelics and IPOs
04 Feb 2026
Contributed by Lukas
Pfizer reported the first data from its new obesity pipeline, picked up in the nearly $10 billion acquisition of Metsera last fall. While BMO Capital ...
Biotech’s New Cycle, JPM Deal Hype and Where Alpha Still Hides
29 Jan 2026
Contributed by Lukas
In this episode of Denatured, Jennifer C. Smith-Parker speaks with RTW’s Rod Wong and Stephanie Sirota how shifting JPM deal timing masks record M&a...
Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More
28 Jan 2026
Contributed by Lukas
Roche made the biggest splash this week so far, announcing on Tuesday that GLP-1/GIP injectable CT-388 led to 22.5%weight loss in a Phase II trial. Th...
From Sound Bites to Signals: Editors Parse Executive and Investor Chatter at JPM
22 Jan 2026
Contributed by Lukas
In this episode of Denatured, BioSpace editorial team members, Senior Editor, Annalee Armstrong, and News Editor, Dan Samorodnitsky, discuss their pos...
JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
21 Jan 2026
Contributed by Lukas
The 2026 J.P. Morgan Healthcare Conference concludedlast week without a big M&A deal. But the meeting was anything but boring, with President Dona...
Bonus: Q4 2025 Job Market Update
19 Jan 2026
Contributed by Lukas
In this episode, BioSpace’s Vice President of Marketing Chantal Dresner and Careers Editor Angela Gabriel discuss Q4 2025 job market performance, ...
Deals Roll at JPM26, Policy Front and Center, IPOs Are Back, FDA Stays Busy
14 Jan 2026
Contributed by Lukas
AbbVie bet nearly $5 billion for the ex-China rights to RemeGen’s PD-1/VEGF bispecific and Novartis struck a $1.5 billion Alzheimer’s-focused deal...
From Nuclear Winter to Renewal: Biotech Investing for 2026
08 Jan 2026
Contributed by Lukas
In this episode of Denatured, Jennifer C. Smith-Parker speaks to Maha Katabi, general partner at Sofinnova Investments and Andrew Lam, managing direct...
Novo Launches Oral Obesity Pill, Lilly Targets Lofty Revenue, FDA and M&A in Focus
07 Jan 2026
Contributed by Lukas
Obesity titans Novo Nordisk and Eli Lilly characteristically kicked off 2026 in the headlines. After capping 2025 with the first-ever FDA approval of ...
Inside the 2026 Biotech Landscape: Innovation, Investment and Global Momentum
18 Dec 2025
Contributed by Lukas
In this episode of Denatured, Jennifer Smith-Parker speaks to Kenneth Galbraith, CEO at Zymeworks and Josh Smiley, president and COO at Zai Lab, about...
Lilly’s Triple Triumph, Prasad’s COVID Error, J&J’s Surprise Voucher, M&A Targets
17 Dec 2025
Contributed by Lukas
Eli Lilly is wrapping up 2025 with record-breaking weight loss in a late-stage trial for its triple hormone receptor agonist retatrutide. Results from...
Beyond the Gluten-Free Diet: A New Era in Celiac Disease Treatment
11 Dec 2025
Contributed by Lukas
In this episode presented by AnaptysBio, Jennifer Smith-Parker speaks to Dr. Joe Murray, professor of medicine, Division of Gastroenterology and Hepa...
Weight Loss Waves, Pazdur’s Exit and FDA Instability, New Neuro Breakthroughs
10 Dec 2025
Contributed by Lukas
Pfizer followed up its winning $10 billion bid forobesity startup Metsera by adding another molecule to its obesity cabinet, thisone from Chinese firm...
New Approach Methodologies: Redefining Animal Testing Alternatives
04 Dec 2025
Contributed by Lukas
Momentum is building behind New Approach Methodologies (NAMs) that offer stronger human relevance than traditional animal testing. The FDA issued on D...
Prasad’s Leaked FDA Memo, Alzheimer’s Ups and Downs, Next-Gen Obesity Drugs
03 Dec 2025
Contributed by Lukas
Vinay Prasad’s memo, leaked over the weekend, has sent vaccine makers’ stocks slipping and experts clamoring for more evidence to support the CBER...
Billions More in M&A, Another Bidding War and More FDA Drama
19 Nov 2025
Contributed by Lukas
Acquisitions have ticked up this month as all eyes were on Pfizer and Novo’s fight over Metsera. The past week saw that deal finalized with Pfizer a...
How Biotech Funding is Changing Executive Search and Hiring Processes
13 Nov 2025
Contributed by Lukas
A lean funding environment has changed how biotechs approach workforce organization and executive hiring. Searches are becoming more targeted and inte...
Pfizer Wins Metsera, Trump Strikes GLP-1 Pricing Deal, FDA Awards More Priority Vouchers
12 Nov 2025
Contributed by Lukas
One of biopharma’s most memorable bidding wars finally came to an end on Friday—with Metsera right back in the arms of its original suitor, but wi...
Thoughtful Tech: How Removing Technological Burdens Can Improve Clinical Trial Compliance and Patient Experience
06 Nov 2025
Contributed by Lukas
This conversation features insights from Oliver Eden, senior business unit director at Jabil, and Travis Webb, chief scientific officer at PII. Our gu...
Pfizer and Novo Battle Over Metsera, Tidmarsh Fights FDA Exit, UniQure and Sarepta Face Setbacks
05 Nov 2025
Contributed by Lukas
Many of the top stories of 2025 are currently being written. We’re on the edge of our keyboards, watching and waiting as Pfizer and Novo Nordisk duk...
Innovation, Resilience, and the Future of Global Manufacturing
30 Oct 2025
Contributed by Lukas
In this episode of Denatured, guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney discuss how China, historically focused on manufacturing, is increasing...
Novartis’ Big Buy, Q3 Earnings, Regeneron’s Dropped Cell Therapy, More
29 Oct 2025
Contributed by Lukas
Novartis started the week early with a Sunday afternoon announcement of the acquisition of neuromuscular drug developer Avidity Biosciences for $12B. ...
How Supply Chain Turbulence is Reshaping Biotech Strategy
23 Oct 2025
Contributed by Lukas
In this episode of Denatured, guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney how in light of economic uncertainty, small biotechs can turn to intern...
Novo Board Upended, ESMO Excitement, FDA Awards, Replimune’s U-Turn
22 Oct 2025
Contributed by Lukas
Novo Nordisk dominated the news cycle this week, with more leadership changes as the Novo Foundation replaced the company’s board, which will now be...
Cost Control to Capability Building: Rethinking Supply and Strategy in Pharma
21 Oct 2025
Contributed by Lukas
In this episode of Denatured, guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney will explore how healthcare and pharmaceutical players — from hospita...
Work Smart, Build Trust: Connecting Technology, Patient Compliance and Data Processing
16 Oct 2025
Contributed by Lukas
This episode continues the discussion with Oliver Eden, senior business unit director at Jabil, and Travis Webb, chief scientific officer at PII, as t...
Q3 Earnings Are Here, Novo Ditches Cell Therapy but Buys Akero, Gov’t Shutdown Hits CDC
15 Oct 2025
Contributed by Lukas
Johnson & Johnson kicked off Q3 earnings season on Tuesday with the announcement that it is splitting its orthopedics and medtech operations and t...
Bonus: Q3 2025 Job Market Update
14 Oct 2025
Contributed by Lukas
In this discussion, BioSpace’s vice president of marketing Chantal Dresner and careers editor Angela Gabriel take a look at ...
Shutdown Pauses New Drug Reviews, CDC Issues New COVID Guidance, CGT Meets on Mesa
08 Oct 2025
Contributed by Lukas
The U.S. government is now in its second week of a shutdown—with the FDA having paused acceptance of all new drug applications for the duration. But...
Hit Me With Your Best Shot: Understanding Autoinjectors and Combination Drug Delivery Systems
02 Oct 2025
Contributed by Lukas
Clinical trials can present many challenges for patients–particularly injections.Oliver Eden, senior business unit director at Jabil, and Travis Web...
M&A Picks Up, Walmsley Moves On, Pfizer’s MFN Deal and Hope for Huntington’s
01 Oct 2025
Contributed by Lukas
Genmab closed out a busy third quarter for M&A in biopharma, picking up cancer biotech Merus for $8 billion. This deal—the year’s fifth larges...
FDA’s Autism Endeavor, Pfizer’s Obesity Comeback Bid, Psychedelics Revival, ACIP Confusion, More
24 Sep 2025
Contributed by Lukas
The FDA is working to reapprove GSK’s long-dormant drug Wellcovorin (leucovorin) for cerebral folate deficiency, which the agency linked to “devel...
What Do AI and Hammers Have in Common?
18 Sep 2025
Contributed by Lukas
In this episode, Lori Ellis and Colin Zick spend a little time further discussing some of the points brought up in the Bioprocessing Summit last month...
China Crackdown, UK Exit, Novo Layoffs, Adcomm Flip Flop, More
17 Sep 2025
Contributed by Lukas
A global shift may be underway in biopharma as the White House prepares legislation that would would place restrictions on drugs brought to the U.S. f...
Unpacking the Latest MAHA Report, RFK’s Senate Appearance, FDA’s CRL Drop and More
10 Sep 2025
Contributed by Lukas
The Make America Healthy Again Commission released itssecond report Tuesday, recommending, among other efforts, an investigation into a possible link ...
The 'Research Safety Net' Saving Scientists from Funding Crisis
04 Sep 2025
Contributed by Lukas
In this episode, Mike Garrett, CEO of Taconic Biosciences, discusses how preclinical research companies are helping drug developers navigate the curre...
CDC Faces Critical Meetings Amid COVID Vaccine Uncertainty, Plus Deals, FDA Approvals, More
03 Sep 2025
Contributed by Lukas
We returned from the Labor Day holiday to a spate of intriguing deals, including two that could surpass $2 billion: Vertex’s new pact with Enlaza fo...
Lilly’s Obesity Pill Heads to the FDA, AbbVie Bets on Psychedelics, HHS Unveils More Change
27 Aug 2025
Contributed by Lukas
Eli Lilly posted data Tuesday from a second Phase III trial of its oral weight loss therapy orforglipron, providing the company with all it needs to h...
Oral Weight-Loss Race Heats Up as New Data From Lilly, Viking Reset Expectations
26 Aug 2025
Contributed by Lukas
Oral therapies are projected to account for 25% of the anti-obesity medication market by 2030—but first returns have largely disappointed. This mont...
Why AI Won't Save the 90% of Clinical Trials That Still Fail
21 Aug 2025
Contributed by Lukas
While AI represents a significant advancement in efficiency for early-stage drug discovery, it won't dramatically change the 90% clinical trial fa...
MAHA Report Emphasizes Vaccines, Safety Vexes Viking’s Obesity Win, Novo Gains Momentum
20 Aug 2025
Contributed by Lukas
Three months after taking heat over an error-riddled first report, Health Secretary Robert F. Kennedy’s Make America Healthy Again Commission was du...
The Hidden Patent Crisis That Could Break Biotech: What Every CEO Needs to Know
14 Aug 2025
Contributed by Lukas
In this Denatured discussion, the conversation revolves around unpacking the patent policy changes that could make or break biotech companies. Guests ...
Prasad Returns, Delany Departs, Lilly’s Weight Loss Pill Disappoints and Sarepta’s Fallout Continues
13 Aug 2025
Contributed by Lukas
Vinay Prasad is back at the FDA as chief of the FDA’s Center for Biologics Evaluation and Research. Prasad’s return—which hit the news wires Sat...
From Chat Bots to World Order: The Race for the 21st Century's Operating System
07 Aug 2025
Contributed by Lukas
In this thought-provoking episode, Cresset Group’s CSO, Mark Mackey, and VP of AI, Mutlu Dogruel, dissect the emerging geopolitical battle for AI su...
FDA In Flux, Pfizer Talks to Trump on MFN, Merck Cuts 6K Jobs, More
06 Aug 2025
Contributed by Lukas
Center for Drug Evaluation and Research Head George Tidmarsh will oversee the Center for Biologics Evaluation and Research on an acting basis after Vi...
We Don't Own Patient Data–We're Just Babysitting It
31 Jul 2025
Contributed by Lukas
While AI excels at repetitive tasks like triaging medical information calls, document retrieval, and adverse event detection, the industry must addres...
Sarepta Gets Reprieve, RFK Jr.’s New Changes, Roche’s Alzheimer’s Comeback and Q2 Earnings
30 Jul 2025
Contributed by Lukas
The Sarepta saga continued into another week as the FDA recommended that the voluntary hold on the company’s Duchenne muscular dystrophy gene therap...
Sarepta’s Wild Week, CDER’s New Leader, FDA Rejections, Manufacturing Billions
23 Jul 2025
Contributed by Lukas
Just a few weeks ago, it seemed like Sarepta had weathered a spate of bad news, after two patients died from liver injuries from its Duchenne muscular...
Why Countries Are Racing to Build mRNA Factories While America Hesitates on Next-Gen Vaccines
22 Jul 2025
Contributed by Lukas
This episode continues the discussion regarding the rapid evolution of mRNA technologies since COVID-19. Guests discuss the improvements that have occ...
AI Is Taking Over Drug Safety Monitoring–But There's One Thing It Can't Replace
17 Jul 2025
Contributed by Lukas
This episode focuses on how AI is transforming pharmacovigilance (PV) on a global scale, particularly focusing on the evolving role of local qualified...
FDA Layoffs, 200 Rejection Letters, User Fees and Priority Vouchers, Bad Week for Rare Disease
16 Jul 2025
Contributed by Lukas
Up to 3,500 FDA staffers received their final walking papers Monday after the U.S. Supreme Court found last week that the government is “likely to s...
Bonus Episode: Q2 2025 Job Market Update
15 Jul 2025
Contributed by Lukas
In this discussion, BioSpace’s vice president of marketing Chantal Dresner and careers editor Angela Gabriel take a look...
The mRNA Revolution You Haven't Heard About: From Cystic Fibrosis to Personalized Cancer Vaccines
10 Jul 2025
Contributed by Lukas
This discussion focuses on how mRNA and self-replicating RNA (srRNA) technologies are expanding far beyond COVID vaccines into revolutionary therapeut...
Second Half Milestones, KalVista’s Surprise Approval, Another RFK Jr. Lawsuit, More
09 Jul 2025
Contributed by Lukas
While most of the U.S. was celebrating the 4th of July holiday, President Donald Trump was busy signing the One Big, Beautiful Bill into law. This wid...
CAR T Expands, M&A Ticks Up, Two Psychedelics Read Out, and the Supreme Court Rules on PrEP
02 Jul 2025
Contributed by Lukas
The U.S. Supreme Court closed out its session before breaking for summer on Friday, ruling that decisions around coverage of HIV PrEP drugs should be ...
Understanding the FDA's AI Guidance in Pharmacovigilance
01 Jul 2025
Contributed by Lukas
In this episode of Denatured, Archana Hegde from IQVIA discusses the practical challenges faced by pharmacovigilance (PV) professionals as they naviga...
FDA Churn Continues, RFK Faces Congress, Obesity Insights at ADA, BIO2025 Recap
25 Jun 2025
Contributed by Lukas
Robert F. Kennedy Jr. testified in front of the House Committee on Energy and Commerce Tuesday, where Democrats confronted the health secretary on hot...
Navigating Funding Freezes and AI Frontiers
19 Jun 2025
Contributed by Lukas
Lori Ellis, head of insights at BioSpace, discusses some of the recent events and topics that are buzzing around BIO and DIA in 2025 with Rich Daly, C...
Another Gene Therapy Death; Biopharma M&A Picks Up; a Vaccine Board of Vaccine Skeptics
18 Jun 2025
Contributed by Lukas
This week, BioSpace is at 50% power as Heather McKenzie and Jef Akst are off attending this year’s BIO Conference in Boston. The half-team discusses...
RFK Axes CDC Vaccine Advisors ; Metsera’s Weight Loss Win; FDA Supports CGT
11 Jun 2025
Contributed by Lukas
This week the BioSpace team was sent into an after-hours scramble by the news that Health and Human Services Secretary Robert F. Kennedy Jr. had fired...
AI's Role in Decoding the FDA's New Regulatory Communications
05 Jun 2025
Contributed by Lukas
In a dynamic regulatory environment, IQVIA’s Michelle Gyzen suggests that AI may be the best and only way to keep with changes that are happening da...
M&A Ticks Up, ASCO Excites and Vaccines Cause More Drama
04 Jun 2025
Contributed by Lukas
The words of the week so far in biopharma are “deals” and “cancer”—or, more specifically, money being invested in cancer and other key thera...
COVID-19 Vaccine Overhaul, Rocket Grounded, ‘One Tough Hombre’ on MFN
28 May 2025
Contributed by Lukas
The name of the biopharma game this season is vaccines—and RFK Jr. wasted no time returning from Memorial Day Weekend before making news on this fro...
How Target Product Profiles Guide the Industry Through Uncertain Times
22 May 2025
Contributed by Lukas
Lori Ellis, head of insights and Ian Fisher, head of development of analytics at IQVIA, discusses the critical importance of Target Product Profiles (...
Pfizer’s $6B China Deal, Drug Pricing and FDA’s New COVID Vaccine Plan
21 May 2025
Contributed by Lukas
Pfizer stole the headlines this week with a pact worth up to $6 billion with Chinese biotech 3SBio for a PD-1/VEGF candidate just three months after i...
Trump’s Drug Pricing Policy, Prasad’s CBER Nod, Bayer’s Layoffs and Galapagos’ Next Chapter
14 May 2025
Contributed by Lukas
President Donald Trump unveiled a sweeping drug pricing policy this week, seeking to lower drug prices in the U.S. by up to 80% through a reprisal of ...
Eroding Immunity: Vaccine Hesitancy and Cynicism
08 May 2025
Contributed by Lukas
Paul Offit, MD, Director of the Vaccine Education Center at the Children's Hospital of Philadelphia and the Maurice R. Hilleman Professor of Vaccinolo...
Trump’s US Manufacturing Push, New Vaccine Policy, Novo’s Weight Loss Pill up for FDA Review
07 May 2025
Contributed by Lukas
In his effort to onshore manufacturing, President Donald Trump issued an executive order on Monday afternoon ordering the FDA to ease permitting proce...
Tariffs Continue to Dominate Q1 Earnings, AACR Excites Cancer Space, CEO Pay Gaps, More
30 Apr 2025
Contributed by Lukas
Policy issues—particularly tariffs—loom large as Q1 2025 earnings season rolls on, with Pfizer , Novartis, AstraZeneca and many more all reporting...
Economic Challenges, Strategic Investments: Reshaping the Women's Health Landscape
24 Apr 2025
Contributed by Lukas
This discussion features BioSpace's head of insights Lori Ellis, Kearney partner Martin Hadosi, and Melissa Laitner, director of strategic initiat...
Makary’s First Interview, US Manufacturing Push and Lilly vs. Novo in Obesity Pill Race
23 Apr 2025
Contributed by Lukas
While much of the country was off celebrating Easter and Passover this weekend, the FDA—and its new leader Marty Makary—were busy making news. Mak...
Tariff Turmoil, FDA’s Future, Pfizer’s Obesity Setback and CEO Salaries Revealed
16 Apr 2025
Contributed by Lukas
It’s all about tariffs again this week. No sooner had Donald Trump announced that “major” tariffs on the pharmaceutical industry would be coming...
Bonus: Q1 2025 Job Market Update
15 Apr 2025
Contributed by Lukas
In this bonus episode, BioSpace’s vice president of marketing Chantal Dresner and careers editor Angela Gabriel take a look at job...
Breaking Down Barriers: The Nuanced Approach to Women's Representation in Medical Research
10 Apr 2025
Contributed by Lukas
This discussion features BioSpace's head of insights Lori Ellis, Kearney partner Martin Hadosi, and Melissa Laitner, director of strategic initiat...
Tariff-Triggered Recession Fears, Fallout From HHS Cuts, Knockoff GLP-1s and More
09 Apr 2025
Contributed by Lukas
Pushback against the Trump administration’s massive government cuts exploded this weekend across America—and biopharma is no exception. Taking a d...
FDA on Fire, Novo’s Mixed Bag of Semaglutide Cardio Data, Kisunla’s EU Miss, More
02 Apr 2025
Contributed by Lukas
Biopharma’s reaction to the forced resignation of venerable CBER director Peter Marks has been swift and furious, with former FDA Commissioner Rober...
Balancing Protection and Inclusion: The Evolution of Women in Clinical Trials
27 Mar 2025
Contributed by Lukas
Martin Hodosi, partner at Kearney and Melissa Laitner, director of strategic initiatives, National Academy of Medicine, join Lori Ellis, head of insig...
Trump’s Pharma Tariffs, Monarez for CDC, Novo’s New Obesity Play, More
26 Mar 2025
Contributed by Lukas
President Donald Trump doubled down on tariff threats targeting pharma, saying additional levies on pharmaceuticals will come “at some point,” per...
Sarepta’s Elevidys Death, FDA’s Vaccine Move, Weldon Whiplash, PDUFAs in Cardio
19 Mar 2025
Contributed by Lukas
A patient with Duchenne muscular dystrophy taking Sarepta’s gene therapy Elevidys has died of acute liver failure, possibly related to a recent vira...
A Conversation With Mark McKenna, CEO of Mirador
18 Mar 2025
Contributed by Lukas
On the sidelines of this year’s J.P. Morgan Healthcare Conference in San Francisco, BioSpace Senior Editor Annalee Armstrong sat down with Mark McK...
“Perfect Patient” Industry Burdens; Exits and Investment in Women’s Health
13 Mar 2025
Contributed by Lukas
Miruna Sasu, CEO of COTA, has been labeled as a disrupter in the industry. In this episode, she discusses the challenges of stringent inclusion and ex...
COVID Reflections, Novo’s Next-Gen Weight Loss Struggles, Another Depression Miss, More
12 Mar 2025
Contributed by Lukas
As we mark five years since the World Health Organization officially declared the COVID-19 pandemic, the BioSpace editorial team reflects on the healt...
Tariff Threat Continues, More Meetings Cancelled, AbbVie Makes Obesity Play, More
05 Mar 2025
Contributed by Lukas
Donald Trump’s tariffs have headlined myriad news stories this week—including at BioSpace, where we reported Pfizer CEO Albert Bourla’s claim th...